Targeted radiopharmaceuticals, which combine cancer-seeking ligands with radioactive isotopes to deliver precision radiation, are emerging as a new frontier of cancer care.
That’s the view of the dealmakers and investors driving a flurry of activity in the space: Bristol Myers Squibb Company’s $4.1bn acquisition of RayzeBio and Eli Lilly and Company’s $1
Promising data from Novartis AG’s flagship duo of marketed radiopharmaceuticals, Lutathera (lutetium 177 dotatate) and Pluvicto (lutetium 177 vipivotide tetraxetan), are fueling the hunt for next-generation approaches that build upon and expand this modality’s applications beyond rare neuroendocrine tumors